Buy this cloud stock that continues to eat up market share, JPMorgan says

JPMorgan upgraded Veeva Systems (VEEV) to Overweight from Neutral, raising its price target to $330, implying a potential 20.9% upside. The upgrade follows Veeva's strong Q2 earnings beat and is driven by the company's consistent 20% revenue growth over the past five years, its substantial $20 billion total addressable market in life sciences, and a new long-term partnership with Iqvia expected to accelerate revenue growth and unlock new monetization opportunities. JPMorgan believes Veeva's competitively differentiated platform and TAM penetration justify a re-rating from its current valuation.

Analysis

JPMorgan has upgraded Veeva Systems (VEEV) to Overweight from Neutral, increasing its price target to $330, which suggests a 20.9% potential upside from current levels. This upgrade is predicated on several key factors, including the company's recent second-quarter revenue and earnings beat, which had already prompted positive revisions from other firms. The analysis highlights Veeva's dominant position and substantial growth trajectory within the life sciences sector, evidenced by a historical 20% revenue growth over the past five years, far outpacing the industry's mid-single-digit expansion. JPMorgan projects a sustained ~13% three-year compound annual growth rate (CAGR) for revenue, coupled with impressive free cash flow (FCF) margins of 40% or higher. A significant catalyst for this optimism is the newly formed long-term partnership with Iqvia, a former competitor, which is expected to unlock new monetization opportunities and accelerate revenue growth. Despite competition from Salesforce, the analyst believes Veeva's differentiated platform, superior product depth, and developments in Agentic AI justify a valuation re-rating from its current 24x CY26E EV/EBITDA multiple, reinforcing a broader bullish consensus where 19 of 32 analysts rate the stock a buy or strong buy.

Key Decisions for Investors

• Investors should view the JPMorgan upgrade and the new Iqvia partnership as significant positive catalysts, potentially justifying initiating or adding to long positions in Veeva Systems given the 20.9% implied upside to the $330 price target.
• The successful execution and monetization of the Iqvia partnership is the core driver of the projected revenue acceleration, and investors must monitor early results and management commentary on this integration.
• While the outlook is strong, continued conviction relies on Veeva meeting JPMorgan's forecast of a ~13% revenue CAGR and 40%+ FCF margins to support a valuation re-rating, especially given its current multiple and competition from Salesforce.